Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Bernstein analyst Courtney Breen maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,300.00. The company’s shares closed yesterday at $977.25.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Moderna, and Pfizer. According to TipRanks, Breen has an average return of 19.0% and an 84.09% success rate on recommended stocks.

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1,271.13, a 30.07% upside from current levels. In a report released on March 9, Citi also maintained a Buy rating on the stock with a $1,500.00 price target.

Based on Eli Lilly & Co’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $19.29 billion and a net profit of $6.64 billion. In comparison, last year the company earned a revenue of $13.53 billion and had a net profit of $4.41 billion

Based on the recent corporate insider activity of 148 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year. Most recently, in January 2026, Lilly Endowment Inc, a Major Shareholder at LLY sold 292,148.00 shares for a total of $322,379,685.16.